Biodesix logo

BiodesixNASDAQ: BDSX

Profile

Sector:

Healthcare

Country:

United States

IPO:

28 October 2020

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$164.38 M
-41%vs. 3y high
51%vs. sector
-vs. 3y high
-vs. sector
-86%vs. 3y high
85%vs. sector
-53%vs. 3y high
44%vs. sector

Price

after hours | 37 min ago
$1.13-$0.11(-8.87%)

Dividend

No data over the past 3 years
$18.15 M$19.83 M
$18.15 M-$10.26 M

Analysts recommendations

Institutional Ownership

BDSX Latest News

Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com20 November 2024 Sentiment: POSITIVE

The heavy selling pressure might have exhausted for Biodesix (BDSX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates
zacks.com01 November 2024 Sentiment: NEUTRAL

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago.

Biodesix Announces Third Quarter 2024 Results and Highlights
globenewswire.com01 November 2024 Sentiment: POSITIVE

Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo.

Biodesix to Participate in Three Investor Conferences in November
globenewswire.com29 October 2024 Sentiment: POSITIVE

LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences:

Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024
businesswire.com18 October 2024 Sentiment: POSITIVE

LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2024 before the start of trading on Friday, November 1. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day. Listeners can register for the webca.

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
businesswire.com07 October 2024 Sentiment: POSITIVE

LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2024 in Boston, Massachusetts on Tuesday, October 8 at 10:20 am ET. The presentation will detail the experience of healthcare providers using the Nodify Lung® Nodule Risk Assessment in over 35,000 patients consecutively tested in a real-world clinical setting. Guidelines recommend that.

Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
zacks.com07 August 2024 Sentiment: POSITIVE

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.17 per share a year ago.

Biodesix Named to Inc. Magazine's 2024 “Best Workplaces”
businesswire.com18 June 2024 Sentiment: POSITIVE

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine's Best Workplaces list. The ranking is a result of a comprehensive, data-driven measurement process to identify which American companies have excelled in creating exceptional workplaces with great company cultures. After collecting data from thousands of submissions, Inc. selected 543 honorees this year. Each company that was nomina.

Biodesix to Participate in Two Investor Conferences in June
businesswire.com28 May 2024 Sentiment: POSITIVE

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44th Annual Growth Stock Conference Presentation and 1x1 Meetings Presentation Date and Time: Tuesday, June 4, 2024 at 10:40 AM CT Location: Chicago, IL Jefferies Global Healthcare Conference Presentation and 1x1 Meetings Presentation Date.

3 Penny Stocks to Turn $999 Into $1 Million: January 2024
InvestorPlace26 January 2024 Sentiment: POSITIVE

Despite the recent economic deceleration, positive factors like a tight labor market and strong consumer spending support a resilient U.S. economy. Goldman Sachs predicts increased state and local government spending, and overall expectations suggest that, while there may be a short slowdown, the U.S. economy is anticipated to remain on a positive trajectory in 2024.

What type of business is Biodesix?

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

What sector is Biodesix in?

Biodesix is in the Healthcare sector

What industry is Biodesix in?

Biodesix is in the Diagnostics & Research industry

What country is Biodesix from?

Biodesix is headquartered in United States

When did Biodesix go public?

Biodesix initial public offering (IPO) was on 28 October 2020

What is Biodesix website?

https://www.biodesix.com

Is Biodesix in the S&P 500?

No, Biodesix is not included in the S&P 500 index

Is Biodesix in the NASDAQ 100?

No, Biodesix is not included in the NASDAQ 100 index

Is Biodesix in the Dow Jones?

No, Biodesix is not included in the Dow Jones index

When was Biodesix the previous earnings report?

No data

When does Biodesix earnings report?

The next expected earnings date for Biodesix is 28 February 2025